Amgen Inc. (NASDAQ:AMGN) Shares Bought by Silver Lake Advisory LLC

Silver Lake Advisory LLC grew its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 38.5% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,076 shares of the medical research company’s stock after purchasing an additional 299 shares during the period. Silver Lake Advisory LLC’s holdings in Amgen were worth $336,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Horizon Financial Services LLC acquired a new position in shares of Amgen in the 1st quarter valued at $28,000. United Community Bank bought a new position in shares of Amgen in the fourth quarter valued at approximately $29,000. Delos Wealth Advisors LLC boosted its holdings in Amgen by 2,500.0% during the fourth quarter. Delos Wealth Advisors LLC now owns 104 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 100 shares during the period. Bbjs Financial Advisors LLC acquired a new stake in shares of Amgen in the second quarter worth $33,000. Finally, Western Pacific Wealth Management LP acquired a new stake in Amgen in the 4th quarter worth $37,000. 76.50% of the stock is currently owned by institutional investors.

Amgen Stock Down 0.5 %

Shares of AMGN opened at $321.44 on Friday. The firm’s 50-day simple moving average is $319.99 and its 200 day simple moving average is $299.35. The company has a debt-to-equity ratio of 11.96, a quick ratio of 0.98 and a current ratio of 1.42. The firm has a market cap of $172.43 billion, a P/E ratio of 45.92, a price-to-earnings-growth ratio of 2.78 and a beta of 0.58. Amgen Inc. has a 52 week low of $248.38 and a 52 week high of $346.85.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, August 6th. The medical research company reported $4.97 earnings per share for the quarter, missing the consensus estimate of $5.01 by ($0.04). The firm had revenue of $8.39 billion for the quarter, compared to analyst estimates of $8.35 billion. Amgen had a return on equity of 156.21% and a net margin of 12.74%. The business’s revenue for the quarter was up 20.1% on a year-over-year basis. During the same period in the previous year, the business posted $5.00 earnings per share. On average, analysts forecast that Amgen Inc. will post 19.5 earnings per share for the current year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 6th. Stockholders of record on Friday, August 16th will be issued a dividend of $2.25 per share. The ex-dividend date of this dividend is Friday, August 16th. This represents a $9.00 annualized dividend and a dividend yield of 2.80%. Amgen’s dividend payout ratio is presently 128.57%.

Wall Street Analyst Weigh In

A number of research analysts have commented on AMGN shares. UBS Group raised their price target on shares of Amgen from $284.00 to $307.00 and gave the stock a “neutral” rating in a research note on Friday, May 3rd. Jefferies Financial Group reaffirmed a “buy” rating and set a $380.00 price objective (up previously from $375.00) on shares of Amgen in a report on Wednesday, August 7th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a $305.00 price target (down previously from $310.00) on shares of Amgen in a research report on Wednesday, August 7th. TD Cowen raised their target price on Amgen from $360.00 to $381.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. Finally, William Blair raised Amgen from a “market perform” rating to an “outperform” rating in a research note on Friday, May 3rd. Eleven investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat, Amgen has a consensus rating of “Moderate Buy” and a consensus target price of $326.89.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.